^
Association details:
| Biomarker: | RUNX1 mutation |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug Class: | Tyrosine kinase inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Cancer-Related Gene Mutations Drive Resistance to the Third-Generation Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia
Published date:
11/03/2022
Excerpt:
...the VAFs of ASXL1G646Wfs*12 mutation significantly-decreased when in the temporarily response (p = 0.05), while significantly-increased when the secondary resistance occurred (p = 0.015, Figure 4A) in the secondary resistant cohort....ASXL1G646Wfs*12, RUNX1, IKZF1, SETBP1 and PHF6 mutations are the key drivers of resistance to 3G-TKI therapy in CML.
DOI:
10.1182/blood-2022-169397
Source:
Title:
308 Correlations between Mutations in Cancer-Related Genes, Therapy Responses and Outcomes of the 3rd Generation Tyrosine Kinase-Inhibitor (TKI) in Persons with Chronic Myeloid Leukemia Failing Prior TKI-Therapy Clinically Relevant Abstract
Published date:
11/04/2021
Excerpt:
We used deep targeted sequencing for cancer-related mutations and Sanger sequencing for BCR::ABL1 on DNA samples from 167 subjects with CML...ASXL1 mutations with a VAF ≥ 17% and PHF6 mutations were associated with poor responses of the 3rd-generation TKI-therapy. STAT5A and RUNX1 mutations and high-risk ACAs were also associated with worse outcomes in persons receiving a 3rd-generation TKI.
